Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New NGS Solutions Provide Powerful Tool for Myeloid Research with Highly Efficient Workflow

By LabMedica International staff writers
Posted on 06 Oct 2022

OGT (Oxford, UK), a Sysmex Group (Kobe, Japan) company, has launched several new solutions to support its growing next-generation sequencing (NGS) portfolio. More...

These include the SureSeq Myeloid Plus panel, which has been designed to detect aberrations in genes implicated in a variety of Myeloid disorders. Additionally, OGT has also launched a new improved library preparation workflow - the OGT Universal NGS Complete Workflow, compatible with its hematology, inherited and rare disease NGS panels - significantly reducing hands-on time and complemented by updated Interpret NGS Analysis software.

The SureSeq Myeloid Plus panel is the most recent addition to OGT’s hematology NGS portfolio. Having been meticulously designed along-side leading cancer experts, the new panel is able to detect a comprehensive range of aberrations including SNVs, indels, ITDs and PTDs within 49 genes. These genes cover those associated with myeloid disorders including acute myeloid leukemia, myeloproliferative neoplasms and myelodysplastic syndrome among others. Thanks to OGT’s vast expertise in bait design, the Myeloid Plus panel delivers unparalleled coverage uniformity for low frequency variants, even in difficult-to-sequence AT/GC rich regions and challenging regions covering ITDs and PTDs, which are common somatic variants in acute myeloid leukemia (AML) often associated with poor prognosis and an aggressive form of the disease. The power of the Myeloid Plus panel stands testament to the benefits of hybridization capture over PCR enrichment for unrivalled levels of sensitivity and uniformity of coverage.

To support researchers using the SureSeq Myeloid Plus panel, and all of OGT’s SureSeq hematology and CytoSure NGS panels, the new Universal NGS Complete Workflow has been developed. By reducing the number of clean-up steps and QC requirements, library preparation can be completed in just four and a half hours, with a 40% saving of hands-on time. By combining several steps, and introducing sample pooling, the reduced workflow complexity not only decreases the potential for error, but also saves on plastic waste and costs.

Compared to the previous SureSeq workflow, the updated version requires no additional expensive laboratory equipment, making the process much more amenable to automation, and therefore ready for the future. To supplement this new and improved workflow, OGT’s renowned Interpret NGS Analysis software (V3.5) has been upgraded with improvements in CNV interpretation, annotation, visualization and sample data import and display. Unlike many other NGS providers, OGT provides complimentary NGS software with its NGS panels, demonstrating the company’s commitment to sharing technology, and technical expertise to support NGS research around the globe.

“At OGT, we are experts in delivering high efficiency NGS workflows with best-in-class gene panels, software, and library preparation solutions,” said Adrian Smith, Chief Executive Officer of OGT. “Thanks to our unmatched expertise in bait design, and through partnering with leading cancer experts, we have developed a powerful tool for myeloid research with a highly efficient workflow. This enables clinical researchers to quickly and confidently detect all relevant variants in one simple assay. NGS is a key area of expertise for OGT, and we have exciting plans and possibilities for the future.”

Related Links:
OGT
Sysmex Group


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.